title: Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.
abstract: BACKGROUND
  Brentuximab vedotin (BV) has demonstrated an extraordinary efficacy in heavily pretreated classical Hodgkin lymphoma (cHL) patients, targeting CD30-positive cells; however, limited data have been reported on the efficacy of BV in cHL patients failing allogeneic stem cell transplantation (allo-SCT). The aim of this study was to retrospectively evaluate the efficacy and safety of BV in a multicenter setting of cHL relapsing or progressing after allo-SCT.
  
  
  METHODS
  Sixteen BV-naïve patients with recurrent cHL after allo-SCT were included in a compassionate use program and treated with intravenous BV at the dose of 1.8 mg/kg of body weight every 3 weeks for a maximum of 16 cycles.
  
  
  RESULTS
  The objective response rate was 69%. Five patients (31%) had complete remission, and 6 (37%) had partial remission. Stable disease was observed in 4 patients (25%), and progressive disease was observed in 1 (6%). After median follow-up of 26 months (range: 5-30 months), median progression-free survival (PFS), overall survival (OS), and duration of response were 7, 25, and 5 months, respectively. The 2-year PFS and OS were 20% and 61%, respectively. Grade 3-4 hematological adverse events included anemia (15%), thrombocytopenia (12%), and neutropenia (18%). Grade 3 peripheral sensory neuropathy occurred in 2 patients (12%).
  
  
  CONCLUSIONS
  BV therapy is an effective and safe approach for achieving transient disease control in cHL patients with failed allo-SCT. To improve disease control, future studies should explore the combination of BV with targeted agents.
authors: Department of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy carmelo.carlostella@cancercenter.humanitas.it.
authors: Carmelo
authors: C
authors: Carlo-Stella
authors: Department of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors: Francesca
authors: F
authors: Ricci
authors: Department of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors: Serena
authors: S
authors: Dalto
authors: Department of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors: Rita
authors: R
authors: Mazza
authors: Department of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors: Michele
authors: M
authors: Malagola
authors: Department of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors: Francesca
authors: F
authors: Patriarca
authors: Department of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors: Simonetta
authors: S
authors: Viviani
authors: Department of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors: Domenico
authors: D
authors: Russo
authors: Department of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors: Laura
authors: L
authors: Giordano
authors: Department of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors: Luca
authors: L
authors: Castagna
authors: Department of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors: Paolo
authors: P
authors: Corradini
authors: Department of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors: Armando
authors: A
authors: Santoro
mesh_terms: D000328:Adult; D000079963:Brentuximab Vedotin; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D007558:Italy; D008297:Male; D011379:Prognosis; D012189:Retrospective Studies; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D018796:Immunoconjugates; D000079963:Brentuximab Vedotin
keywords: Allogeneic stem cell transplantation; Brentuximab vedotin; CD30; Relapsed or refractory Hodgkin lymphoma; Targeted therapy